HELSINN HLTHCARE — Patent Portfolio
1 drug with active patents · 12 active patents · 0 expired · 0 biologics with BPCIA exclusivity
Verdict HELSINN HLTHCARE's portfolio is moderately strong with a significant cliff year in 2030 and no revenue at risk in the next 5 years.
Portfolio overview HELSINN HLTHCARE has a total of 3 drugs in its portfolio, with 1 of them having patents. The company has a total of 12 US patents, all of which are active. The average vulnerability score of the company's patents is 47, indicating a moderate level of vulnerability. Out of the total patents, 4 are considered ironclad, while 3 are vulnerable. The company does not have any biologics in its portfolio.
Cliff calendar In 2030, 1 drug will lose exclusivity, including Akynzeo. This marks a significant cliff year for the company. Additionally, the company will see 0 drugs lose exclusivity in 2028 and 0 in 2029.
Most exposed drugs The top drug facing near-term loss of exclusivity is Akynzeo, with an earliest active patent expiry date of 2030-11-18, an average vulnerability score of 47, and no annual revenue data available. Akynzeo has 12 patents and is the only drug in the portfolio with a significant patent estate.
Biologic exclusivity HELSINN HLTHCARE does not have any biologics in its portfolio, and therefore, there are no biologics with BPCIA 12-year reference product exclusivity.
Strategic implications The company has no revenue at risk in the next 5 years. However, the loss of exclusivity of Akynzeo in 2030 will likely have a significant impact on the company's revenue. To mitigate this risk, the company may consider lifecycle moves such as subQ switches, label extensions, or combination filings.
Loss of exclusivity calendar · next 12 years
Drugs facing US patent or BPCIA biologic exclusivity loss per year. Click any year to see the broader cliff calendar for the industry.
Patent estate by drug
Akynzeo (NETUPITANT)
Cliff 2030 · 4y-
US12042494
Vuln 81
2030-11-18
This patent protects compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
-
US11559523
Vuln 76
2030-11-18
This patent protects compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.
-
US8623826
Vuln 73
2030-11-18
This patent protects methods for treating nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery by co-administering netupitant, palonosetron, and dexame…
Patent classification breakdown · active patents
By US patent type. Method-of-use patents are most vulnerable to design-around; composition-of-matter patents are the strongest protection.
- Method of Use 7 patents
- Composition of Matter 4 patents
- Formulation 1 patent
Sources
- FDA Orange Book — small-molecule patents listed against approved NDAs.
- FDA Purple Book — biologic BPCIA 12-year reference product exclusivity.
- USPTO Patent Public Search — title, abstract, claim text grounding.
- AI summaries generated by Drug Landscape, grounded in source claim text.
Patent term extensions (PTR, SPC, pediatric exclusivity) may shift effective expiry. Not legal advice.
Track HELSINN HLTHCARE's patent estate
Daily alerts when vulnerability scores shift, patents expire, or IPRs are filed. Free tier: 3 watches. Pro tier (£199/mo): 50 watches + daily AI Pharma IP Brief.
↓ CSV export